AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31993192
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation of 12 vitamins and 5 minerals for 6 weeks (Pool 2)
Trial: 31993192
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation of 12 vitamins and 5 minerals for 6 weeks (Pool 1)
Trial: 31993192
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation of 12 vitamins and 5 minerals for 6 weeks (both pools)
Trial: 31993275
Drug: Herbal gel
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal gel (Hiora SG)
Trial: 31995012
Drug: Benidipine +
RxNorm normalized name: manidipine
DrugBank: Manidipine (DB09238)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benidipine + β-blocker (n=1,089)
Trial: 31995012
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three regimens (benidipine + ARB, β-blocker, thiazide)
Trial: 31996201
Drug: Trans-oral endoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-oral endoscopic thyroid surgery
Trial: 31998285
Drug: Neonatal antibiotic
RxNorm normalized name: Foreskin fibroblast (neonatal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neonatal antibiotic treatment
Trial: 31998643
Drug: High-dose ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: High-dose ipilimumab (IPI) 10 mg/kg IV every 3 weeks for four doses starting at week 1 and high-dose interleukin-2 (IL-2) 600,000 IU/kg IV bolus every 8 h for up to 14 doses concurrently with IPI at weeks 4 and 7.
Trial: 31998643
Drug: Maintenance IPI
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance IPI (10 mg/kg IV) monotherapy administered every 12 weeks for up to 1 year after the first 12 weeks of combination therapy.
Trial: 31998643
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with high-dose IPI and high-dose IL-2.